(Sharecast News) - UBS upgraded Rentokil Initial on Thursday to 'buy' from 'neutral' and lifted the price target to 540p from 430p.
The bank noted it's been broadly cautious on Rentokil since its 2022 Terminix acquisition, but said that last year's strategy reshaping means it now sees realistic potential for volumes...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE